Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma
Public ClinicalTrials.gov record NCT00689936. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Randomized, Open-label, 3-arm Study to Determine the Efficacy and Safety of Lenalidomide(REVLIMID) Plus Low-dose Dexamethasone When Given Until Progressive Disease or for 18 Four-week Cycles Versus the Combination of Melphalan, Prednisone, and Thalidomide Given for 12 Six-week Cycles in Patients With Previously Untreated Multiple Myeloma Who Are Either 65 Years of Age or Older or Not Candidates for Stem Cell Transplantation.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to compare the safety and efficacy of Lenalidomide plus low dose dexamethasone to that of the combination of melphalan, prednisone and thalidomide.
Study identification
- NCT ID
- NCT00689936
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,623 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 21, 2008 (Actual)
- Primary completion
- Jul 14, 2016 (Actual)
- Completion
- Jul 14, 2016 (Actual)
- Last update posted
- Nov 20, 2019
2008 – 2016
United States locations
- U.S. sites
- 32
- U.S. states
- 17
- U.S. cities
- 28
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of AL Birmingham | Birmingham | Alabama | 35294 | — |
| Cedar Sinai Medical Center Dept of Medicine | Los Angeles | California | 90048 | — |
| University of California, San Francisco- California | San Francisco | California | 94143 | — |
| Stanford University Stanford | Stanford | California | 94305 | — |
| Gainesville Heme Oncology Associates | Gainesville | Florida | 32607 | — |
| Baptist Cancer Institute | Jacksonville | Florida | 32207 | — |
| Integrated Community Oncology Network | Orange Park | Florida | 32073 | — |
| Gulf Coast Oncology | St. Petersburg | Florida | 33705 | — |
| Palm Beach Cancer Institute, LLC | West Palm Beach | Florida | 33401 | — |
| Southern Illinois Hematology Oncology | Centralia | Illinois | 62801 | — |
| Orchard Healthcare Research, Inc. | Chicago | Illinois | 60611 | — |
| John H Stroger Hospital of Cook County | Chicago | Illinois | 60612 | — |
| Rush University Medical Center | Chicago | Illinois | 60612 | — |
| Ingalls Cancer Institute | Harvey | Illinois | 60426-3558 | — |
| Cancer Center of Kansas | Wichita | Kansas | 67124 | — |
| Maine Center for Cancer Medicine Blood Disorders | Scarborough | Maine | 04074 | — |
| Center for Cancer and Blood Disorders | Bethesda | Maryland | 20817 | — |
| Mayo Clinic Cancer Center | Rochester | Minnesota | 55905 | — |
| Billings Clinic | Billings | Montana | 59107 | — |
| Arena Oncology Associates, PC | Lake Success | New York | 11042 | — |
| Dakota Cancer Institute | Fargo | North Dakota | 58103 | — |
| Gabrail Cancer Center Research | Canton | Ohio | 44718 | — |
| University Hospitals of Cleveland | Cleveland | Ohio | 44106 | — |
| Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| Kaiser Permanente Northwest Oncology Hematology | Portland | Oregon | 97227 | — |
| St. Luke's Hospital and Health Network | Allentown | Pennsylvania | 18104 | — |
| University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
| The Cancer Center | Collierville | Tennessee | 38017 | — |
| University of Tennessee Cancer Institute | Memphis | Tennessee | 38104 | — |
| University of Texas Medical Branch | Galveston | Texas | 77555-0561 | — |
| Swedish Cancer Institute | Seattle | Washington | 98104 | — |
| Fred Hutchinson Cancer Center | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 256 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00689936, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 20, 2019 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00689936 live on ClinicalTrials.gov.